Simulations Plus, Inc.

NASDAQ:SLP

Medical - Healthcare Information Services

Healthcare
$18.50 +0.11%

+$0.02 today

Market cap
$374.16M
Beta
1.32
P/E (TTM)
-5.9
EPS (TTM)
-$3.12
52W Low $11.09High $21.01

Volume 0.00M

Average 0.35M

SLP Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Simulations Plus, Inc.NASDAQ: SLP

Cost of Revenue · Q2 FY2026 · quarter ended Feb 2026

Cost of revenue declines year over year

Q2 FY2026 cost of revenue of $8.15M fell 12.4% year over year, in line with the -12.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 8.2% from the prior quarter. Over 3 fiscal years it compounded at +44.9% a year.

Context

  • Cost of revenue amounted to 41.6% of revenue in FY2025, up 3.3 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -12.4% holds above the trailing-twelve-month pace of -12.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterFeb 2026
$8.15M+8.2% QoQ
Last fiscal yearAug 2025
$32.96M+22.7% YoY
LTMFeb 2026
$30.63M-12.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.4%——
1 year+22.7%——
3-year CAGR+44.9%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
32.96M USD
Year-over-year change
+22.7%
4-year CAGR
+32.8%

Cost of Revenue vs competitors

How SLP compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -12.8% is the lowest of 9, against a peer median of +19.3%.
  • Cost of revenue amounts to 38.0% of revenue for SLP, versus a peer median of 31.0%.
SLP Competitors
Cost of Revenue for SLP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGLAgilon Health, Inc.LTM Mar 2026$5.98B USD-0.5%+39.0%102.7%
DHDefinitive Healthcare Corp.LTM Mar 2026$65.42M USD+14.6%+11.0%27.5%
NRCNational Research CorporationLTM Mar 2026$61.21M USD+6.1%+1.7%44.2%
OPRXOptimizeRx CorporationLTM Mar 2026$33.23M USD-1.8%+19.6%31.0%
SLPSimulations Plus, Inc.LTM Feb 2026$30.63M USD-12.8%+44.9%38.0%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$26.56M USD+23.9%+21.8%32.7%
NAKANakamoto Inc.LTM Mar 2026$18.66M USD+353.9%+317.5%476.0%
CLLSCellectis S.A.LTM Mar 2026$12.33M USD+39.3%+4.9%18.1%
KRROKorro Bio, Inc.LTM Mar 2026$1.03M USD——26.8%
ANROAlto Neuroscience, Inc.LTM Mar 2026$284K USD+67.1%+24.6%—
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
Peer median (excluding SLP) —+19.3%+20.7%31.0%

Competitors are the stored peer set for SLP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Aug 2023
FY2024
Aug 2024
FY2025
Aug 2025
Revenue46.47M53.91M59.58M70.01M79.18M
Cost of Revenue10.6M10.82M11.63M26.86M32.96M
Gross Profit35.87M43.08M47.95M43.15M46.22M
Gross Margin77.2%79.9%80.5%61.6%58.4%
Research & Development4.05M3.21M4.5M5.75M6.88M
Selling, General & Admin20.57M24.97M34.72M31.27M32.85M
Operating Expenses24.61M28.17M39.22M37.02M116.95M
Depreciation & Amortization3.59M3.57M3.84M5.67M8.21M
EBITDA14.7M18.69M13.07M18.08M14.7M
EBITDA Margin31.6%34.7%21.9%25.8%18.6%
Operating Income11.25M14.91M8.73M6.13M(70.73M)
Operating Margin24.2%27.7%14.6%8.8%-89.3%
Interest Income201K717K4.13M4.38M722K
Interest Expense22K0000
Other Income / Expenses(168K)204K2.97M6.28M1.35M
Income Before Tax11.09M15.12M11.7M12.41M(69.38M)
Pre-Tax Margin23.9%28.0%19.6%17.7%-87.6%
Income Tax Expense1.3M2.63M1.73M2.46M(4.66M)
Net Income9.78M12.48M9.96M9.95M(64.72M)
Net Margin21.1%23.2%16.7%14.2%-81.7%
EPS (Basic)0.490.620.500.50(3.22)
EPS (Diluted)0.470.600.490.49(3.22)
Weighted Avg Shares20.05M20.2M20.08M19.99M20.1M
Weighted Avg Shares (Diluted)20.74M20.75M20.47M20.3M20.1M

Simulations Plus, Inc.

NASDAQ:SLP

Intrinsic Alpha fair value

Locked

Current Price

$18.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.